Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sen. Joe Manchin (D-W.Va.) Photo: Alex Wong/Getty Images

Sen. Joe Manchin will not support the president's Build Back Better legislation, he told "Fox News Sunday," all but guaranteeing the end of the $1.75 trillion spending package that is the centerpiece of the Biden agenda.

Driving the news: A Manchin staffer reached out to the White House and leadership roughly 30 minutes before his interview, two sources familiar with the West Virginia Democrat's remarks told Axios.

  • And in a statement after his appearance, Manchin doubled down, saying his "Democratic colleagues in Washington are determined to dramatically reshape our society in a way that leaves our country even more vulnerable to the threats we face. I cannot take that risk."
  • While it's still unclear what became the final straw for Manchin, President Biden and the senator had been locked in a disagreement over how long BBB programs should be funded, people familiar with the matter told Axios on Wednesday.
  • "My concerns have only increased as the pandemic surges on, inflation rises and geopolitical uncertainty increases around the world," Manchin said in the Sunday statement.

White House press secretary Jen Psaki responded in a statement Sunday that said, in part: "Sen. Manchin promised to continue conversations in the days ahead, and to work with us to reach that common ground."

  • "If his comments on Fox and written statement indicate an end to that effort, they represent a sudden and inexplicable reversal in his position, and a breach of his commitments to the president and the senator’s colleagues in the House and Senate."

Biden told Manchin in a Monday phone call that he didn't want to budge from his plan to fund some of his programs for one year, and others for 10 years, Axios reported at the time.

  • Manchin was equally clear: Before negotiating which individual programs should survive, he wants to agree to a common denominator for their funding term.

Between the lines: Democratic senators feel blindsided. Multiple members were not given a heads up about the change or the decision to announce it on "Fox News Sunday" morning, and their offices are now scrambling to hold meetings with their staff over how to respond, Senate aides tell Axios.

But, but, but: It's clear Manchin doesn't support the Build Back Better package as it stands now. But it's still unclear whether he'll get behind separate legislation passing some of these key provisions.

  • "BBB is dead," a source familiar with Manchin's remarks makes clear to Axios. "Anything else is hypothetical at this point."

What he's saying: “For five and a half months, I have worked as diligently as possible meeting with President Biden, Majority Leader Schumer, Speaker Pelosi and my colleagues on every end of the political spectrum to determine the best path forward despite my serious reservations," Manchin said in a statement.

  • "I have made my concerns clear through public statements, op-eds and private conversations," he said, adding: “I have always said, ‘If I can’t go back home and explain it, I can’t vote for it.’ Despite my best efforts, I cannot explain the sweeping Build Back Better Act in West Virginia and I cannot vote to move forward on this mammoth piece of legislation."

Go deeper:

Editor's note: This is a developing story and has been updated throughout.

Go deeper

Arkansas Senators: Don't bust filibuster

Sen. Tom Cotton; Photo: Tasos Katopodis/UPI/Bloomberg via Getty Images. Sen. John Boozman; Photo: Tom Williams/CQ-Roll Call, Inc via Getty Images

Both of Arkansas' Republican Sens. John Boozman and Tom Cotton made statements this week in defense of the chamber's filibuster rule.

Driving the news: President Biden attended the Senate Democratic caucus lunch Thursday to make a case for reforming the filibuster to pass voting rights legislation.

Pence: "Tragic" Jan. 6 no reason to scrap filibuster

Photo: Drew Angerer via Getty Images

Former Vice President Mike Pence on Friday called the Jan. 6 Capitol riot an attempt to "overturn results of the presidential election that had been certified by all 50 states."

Why it matters: Though the former vice president's op-ed in the Washington Post focuses on rebutting filibuster reforms, these are also the most public statements Pence has made about the post-election narrative and the attack as an effort to interfere with President Biden's victory.

FDA limits use of Regeneron and Lilly COVID antibody treatments

A coldbox containing monoclonal antibody treatments at a Regeneron clinic in Pembroke Pines, Florida, in August. Photo: Eva Marie Uzcategui/Bloomberg via Getty Images

The FDA said Monday it's limiting the use of two monoclonal antibody therapies as COVID-19 treatments because data indicates they're "highly unlikely" to be effective against the dominant Omicron variant.

Driving the news: The FDA revised the authorizations for Regeneron and Eli Lilly "to limit their use to only when the patient is likely to have been infected with or exposed to a variant that is susceptible to these treatments," per a statement from the agency.